Stock Events

Stock Events

Cg Oncology 

$67.18
5
-$0.53-0.78% Tuesday 20:00

Statistics

Day High
69.69
Day Low
66.42
52W High
73.43
52W Low
21.7
Volume
731,340
Avg. Volume
-
Mkt Cap
5.67B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.6
-0.5
-0.4
-0.3
Expected EPS
-0.555732
Actual EPS
N/A

Financials

-3,985.02%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
8.08MRevenue
-321.99MNet Income

Analyst Ratings

80.83Average Price Target
The highest estimate is 100.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGON. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb is involved in developing cancer immunotherapies, directly competing in the oncology space.
Merck
MRK
Mkt Cap277.02B
Merck is known for its strong portfolio in oncology, including immunotherapy drugs that compete in similar markets as CG Oncology.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad range of cancer treatments, including vaccines and advanced biologics, competing in the oncology sector.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca focuses on various cancer drugs, including those for conditions directly targeted by CG Oncology's pipeline.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, through its acquisition of Kite Pharma, has become a significant player in the cancer therapy field, overlapping with CG Oncology's focus areas.
Novartis
NVS
Mkt Cap279.67B
Novartis offers advanced cancer treatments, including gene therapy and immunotherapy, competing in the same therapeutic areas as CG Oncology.
AMGEN
AMGN
Mkt Cap178B
Amgen develops targeted therapies and immunotherapies for cancer, aligning them as a competitor in the oncology market.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG, with its extensive cancer drug portfolio, competes directly in the oncology market, impacting CG Oncology's market share.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals focuses on innovative biologics in oncology, which competes with CG Oncology's approach to cancer treatment.
Exelixis
EXEL
Mkt Cap11.1B
Exelixis is involved in the discovery, development, and commercialization of new cancer therapies, competing in similar therapeutic areas as CG Oncology.

About

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Show more...
CEO
Mr. Arthur Kuan
Employees
113
Country
United States
ISIN
US1569441009

Listings

XNAS
US
CGON
BOATS
BOATS
CGON.BOATS

0 Comments

Share your thoughts

FAQ

What is Cg Oncology stock price today?▼
The current price of CGON is $67.18 USD — it has decreased by -0.78% in the past 24 hours. Watch Cg Oncology stock price performance more closely on the chart.
What is Cg Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cg Oncology stocks are traded under the ticker CGON.
Is Cg Oncology stock price growing?▼
CGON stock has risen by +3.75% compared to the previous week, the month change is a -0.56% fall, over the last year Cg Oncology has showed a +209.56% increase.
What is Cg Oncology market cap?▼
Today Cg Oncology has the market capitalization of 5.67B
When is the next Cg Oncology earnings date?▼
Cg Oncology is going to release the next earnings report on May 07, 2026.
What were Cg Oncology earnings last quarter?▼
CGON earnings for the last quarter are -0.55 USD per share, whereas the estimation was -0.6 USD resulting in a +8.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cg Oncology revenue for the last year?▼
Cg Oncology revenue for the last year amounts to 8.08M USD.
What is Cg Oncology net income for the last year?▼
CGON net income for the last year is -321.99M USD.
How many employees does Cg Oncology have?▼
As of May 06, 2026, the company has 113 employees.
In which sector is Cg Oncology located?▼
Cg Oncology operates in the Health & Wellness sector.
When did Cg Oncology complete a stock split?▼
Cg Oncology has not had any recent stock splits.
Where is Cg Oncology headquartered?▼
Cg Oncology is headquartered in Irvine, United States.